Form 4: Core Scientific Exec Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. reports that Chief Legal and Administrative Officer Todd DuChene sold 10,000 shares of common stock for $19.7952 per share, executed under a pre-arranged trading plan.

Summary

• Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., sold 10,000 shares of common stock.
• The transaction occurred on April 20, 2026, with a weighted average sale price of $19.7952 per share.
• These sales were conducted as part of a Rule 10b5-1 trading plan established on December 5, 2025.
• The shares were sold at prices ranging from $19.53 to $20.08.
• Following the transaction, DuChene beneficially owns 2,000,348 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the transaction was conducted under a pre-arranged 10b5-1 plan, which is a standard and often necessary tool for executives to manage their stock holdings.

Negatives

• Sale of a significant number of shares by a key executive, which could be perceived negatively by the market.

Risks

• The filing does not explicitly mention any new risks. However, executive stock sales can sometimes be interpreted as a lack of confidence in future stock performance, although this sale was conducted under a pre-established 10b5-1 plan.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The sale was executed under a pre-determined plan, suggesting it was planned in advance and not necessarily indicative of a change in the company's future outlook.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.53 to $20.08, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes create short-term negative sentiment. However, the existence of the plan itself is designed to mitigate concerns about opportunistic trading based on non-public information.

Stakeholder Impact

• Shareholders: May view the sale with caution, although the 10b5-1 plan mitigates concerns about insider trading. The sale does reduce the reporting person's direct stake in the company.
• Employees: Similar to shareholders, the impact is likely minimal unless the sale is interpreted as a negative signal about the company's future prospects.
• Creditors/Suppliers: No direct impact is expected from this transaction.

Next Steps

• The reporting person may continue to execute trades under the existing 10b5-1 plan.
• The company may provide further information upon request from the SEC or security holders regarding the specific sale prices.

Key Dates

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Todd DuChene, Executive Compensation, Beneficial Ownership